FDA Warns of Dosing Errors with Compounded Semaglutide Injectables
XTalks
JULY 26, 2024
The FDA has issued a warning about dosing errors and subsequent adverse events related to compounded semaglutide injectable products. These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. These errors have led to some patients being hospitalized due to overdoses.
Let's personalize your content